Illuminant recently completed a preliminary cadaveric study at the Rhode Island Health Orthopedic Foundation, where neurosurgeons from Mount Sinai and Massachusetts General Hospital successfully placed thoracolumbar instrumentation using Illuminant’s platform. Postoperative scans confirmed high navigational accuracy, validating the system’s potential for clinical use and further regulatory approval efforts.

These cadaveric studies serve as critical validation points in Illuminant’s path to market. By rigorously testing its system in controlled, high-fidelity environments, the company demonstrates its ability to meet the precision and reliability standards required for patient safety and widespread adoption in operating rooms worldwide.